In spite of extensive studies on their activities, [5] [6] [7] [8] [9] their effects on neuronal cell death have not been tested. Here we examined the effects of compounds that were extracted from two Rhodiola plants and Tokaku-joki-to against Ab-induced neuronal cell death, oxidative stress and apoptosis.
MATERIALS AND METHODS
Fifty-six compounds (1-35, 37, 39-58) were isolated from two Rhodiola plants, R. sacra and R. sachalinensis, and a Kampo formula Tokaku-joki-to (Kotaro Kampo, Japan), as previously reported. [10] [11] [12] Hydroquinone (1), 4-hydroxybenzoic acid (2) , b-D-glucopyranosyl 4-hydroxybenzoic acid (3), protocatechuic acid (4), gallic acid (5), 4-hydroxycinnamic acid (8) , caffeic acid (9), 2-phenylethyl b-D-glucopyranoside (13), 2-phenylethyl a-L-arabinopyranosyl-(1→6)-b-D-glucopyranoside (14) , rhodiocyanoside A (17), sarmentosin (18) , heterodendorin (20) (58) were isolated from Tokaku-joki-to (Fig. 1) . Note that some compounds were isolated from more than one source. Two compounds, (ϩ)-catechin (36) and (ϩ)-gallocatechin (38), were purchased from Funakoshi (Tokyo, Japan).
Rat brain-derived B103 cells, which do not express endogenous amyloid precursor protein, 13) were used in the present study. B103 cells were grown in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal bovine serum and 5% penicillin/streptomycin. At the outset, 90% confluent cells were dissociated and plated at 5ϫ10 3 cells/well in a 96-well plate. When the cells were attached to the plate, the medium was replaced with plain DMEM. Cell death was induced by adding Ab 25-35 , H 2 O 2 , or staurosporine in the culture for 24 h. Ab 25-35 was prepared as a 10 mM stock solution in dimethyl sulfoxide (DMSO) and diluted with phosphate buffered saline to induce aggregation. H 2 O 2 was prepared as a 30% stock solution in water and freshly diluted with water before each use. Staurosporine was prepared as a 1 mM stock solution in DMSO and diluted with water to make a 500 nM working solution. The extracted compounds were treated 1 h before adding each toxicant to the medium. The final concentration of each compound was 10 mM throughout the experiments. Ab 25-35 was purchased from US Peptide (Fullerton, CA, U.S.A.). DMEM, fetal bovine serum and penicillin/streptomycin were purchased from GibcoBRL (Grand Island, NY, U.S.A.). All other chemicals were purchased from Sigma (St. Louis, MO, U.S.A.). B103 cells were generously provided by Dr. David Schubert (Salk Institute, La Jolla, CA, U.S.A.).
The degree of cell survival was quantified using 3-(4,5-dimethylthiazol-2-yl)-2,5-dimethyltetrazolium bromide (MTT) assay. 14) At the end of cell culture, MTT was added to the culture (1 : 10 v : v; MTT solution/culture medium) and incubated for 4 h at 37°C. Cells were then solubilized in 50% dimethylformamide and 10% sodium dodecyl sulfide (pH 4.7). The degree of cell survival was determined based on the absorbance measured at O.D. 570-630 nm using a plate reader (Bio-Tek Instruments, Winooski, VT, U.S.A.). The effect of each extract on cell death was assessed in quadruplicate, and the data are expressed as the meanϮS.E.M.
RESULTS AND DISCUSSION
Following treatment of 25 mM Ab 25-35 for 18 h, cell survival was reduced to 63.5Ϯ2.6% of the control culture (36.5% cell death). Of the 58 compounds that were cotreated with Ab, six (22, 40, 44, 49-51) showed more than 10% enhancement of cell survival at 10 mM compared to the Ab treatment group. Ten % enhancement of cell survival compared to control level amounts to ca. 27% blockade of Ab-induced cell death. The degrees of cell survival ranged from 77.2Ϯ6.5 to 86.0Ϯ2.5% of the control level (37.5-61.6% blockade of Ab-induced cell death). This is comparable to the level of cell protection by estrogen (ca. 36% blockade of Ab-induced cell death) under a similar experimental condition. 20) Table 1 shows the effects of all 58 compounds on Ab-induced B103 cell death.
We further tested the effects of the six compounds that showed substantial protective effects against Ab toxicity, against oxidative stress and apoptosis. Staurosporine is known to induce apoptotic cell death. 13) Treatment with 50 nM staurosporine for 18 h reduced cell survival to 37.2Ϯ0.5% of the control culture (62.8% cell death). All six compounds that showed protective effects against Ab toxicity enhanced cell survival when treated together with staurosporine (Fig. 2B) . The degrees of cell survival were between 50.3Ϯ0.8% and 63.6Ϯ1.1% of the control level (20.9-42.0% blockade of staurosporine-induced cell death).
The main objective of the present study was to test whether compounds isolated from R. sacra, R. sachalinensis and Tokaku-joki-to protect neurons against beta-amyloid toxicity. Of the 58 tested compounds, six (22, 40, 44, 49-51) protected B103 cells from Ab-induced cell death in a considerable manner (enhancement Ͼ10% of the control). The nature of Ab-induced cell death is not entirely clear. Previous studies suggest that apoptotic cell death, oxidative stress and necrotic cell death are all involved in Ab-induced cell death. [15] [16] [17] [18] [19] [20] In the present study, we examined the antioxidative and antiapoptotic effects of the six compounds that protected neurons from Ab toxicity. The results show that all of them had antiapoptotic effects, whereas two compounds (22, , and the degree of cell survival was assessed using MTT assay. The values indicate the degree of cell survival expressed as a % of the control level (meanϮS.E.M.).
44)
had additional antioxidative effects. Thus, the neuroprotective effects of the six compounds against Ab toxicity are probably based on both antiapoptotic and antioxidative effects, but antiapoptotic effects appear to play a more important role.
It was difficult to assess the structure-activity relationship of the tested compounds based on the current results. Future studies are required for clear elucidation of structures that are responsible for the neuroprotective effects. Improvement of neuroprotective effects by synthetic modification based on the structure-activity relationship may lead to development of new drugs for AD. Vol. 25, No. 8 
